Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

5.24
+0.13002.54%
Post-market: 5.18-0.0600-1.15%17:40 EDT
Volume:2.16M
Turnover:11.33M
Market Cap:657.36M
PE:-8.05
High:5.35
Open:5.15
Low:5.09
Close:5.11
52wk High:7.55
52wk Low:2.93
Shares:125.45M
Float Shares:115.00M
Volume Ratio:0.71
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6512
EPS(LYR):-0.7836
ROE:148.50%
ROA:-29.20%
PB:-11.62
PE(LYR):-6.69

Loading ...

Aquestive Therapeutics, Inc. Q1 Adjusted Ebitda USD -1.773 Million

THOMSON REUTERS
·
May 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Aquestive Therapeutics Completes $150 Million Debt Refinancing With Oaktree

THOMSON REUTERS
·
May 12

Press Release: Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Dow Jones
·
May 12

Aquestive Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
May 12

Aquestive Therapeutics updates financial calendar for first-quarter results, investor call

Reuters
·
May 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

Aquestive Therapeutics announces annual shareholder meeting

Reuters
·
Apr 25

Aquestive Therapeutics CLO Thomas Zalewski files initial beneficial ownership statement

Reuters
·
Apr 10

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline

TIPRANKS
·
Apr 01

Aquestive plans PK, human factors studies ahead of Anaphylm NDA resubmission in Q3 2026

Reuters
·
Mar 30

Aquestive Therapeutics Inc - Receives Clarifying Feedback From FDA on Pharmacokinetic (Pk) & Human Factor (HF) Study Designs

THOMSON REUTERS
·
Mar 30

Aquestive Therapeutics Inc - Continues to Advance Regulatory Submissions for Anaphylm in Canada and the European Union

THOMSON REUTERS
·
Mar 30

Aquestive Therapeutics Inc - Reaffirms Guidance to Resubmit Anaphylm Nda in Q3 2026

THOMSON REUTERS
·
Mar 30

Aquestive Therapeutics Announces Completion of Type a Meeting With FDA for Anaphylm™ (Dibutepinephrine) Sublingual Film

THOMSON REUTERS
·
Mar 30

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

GlobeNewswire
·
Mar 30

Aquestive Therapeutics faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies

Reuters
·
Mar 26

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

TIPRANKS
·
Mar 20

Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

Dow Jones
·
Mar 20

Class action lawsuit targets Aquestive Therapeutics over alleged securities law violations

Reuters
·
Mar 20